Navigation Links
BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development

PRINCETON, N.J. and WALTHAM, Mass., Oct. 21 /PRNewswire/ -- BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

The agreement grants NKTT non-exclusive rights to research, develop, manufacture and commercialize antibodies targeting natural killer T (NKT) cells that incorporate BioWa technology. NKT cells are a rare but central component of the human immune system, which play a pivotal role in human health and disease. In return, BioWa will receive an upfront payment, development milestone payments and royalties on products. Other details of the agreement are not disclosed.

"We are excited that we have been able to partner with a small venture backed company like NKT Therapeutics. In large part, our decision to partner with NKTT was driven by our interest in NKTT's cell biology and exciting product programs," said Dr. Masamichi Koike, President and CEO of BioWa. "We were able to reach an arrangement that works for a small company like NKTT."

"We believe that the collaboration with BioWa, Inc. will accelerate our development activities in therapeutic antibodies targeting NKT cells, a field that is expected to be a potentially important source of new medicines to satisfy unmet medical needs," said Robert Mashal, M.D., President and CEO of NKTT. "We are pleased with BioWa's flexibility to adapt its normal business terms to make this collaboration possible."

About POTELLIGENT(®) Technology

POTELLIGENT(®) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(®) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(®) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(®) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(®) platform. AccretaMab(®) platform consists of POTELLIGENT(®) and COMPLEGENT(®) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(®) and COMPLEGENT(®) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT(®), COMPLEGENT(®), and AccretaMab(®) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About NKT Therapeutics

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat asthma, cancer, infectious diseases, autoimmune diseases, and dermatitis. For more information about NKTT, visit its web site at

SOURCE BioWa, Inc.

SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
2. BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
3. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
4. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
7. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
8. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
9. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
10. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
11. Professional Pricing Society Announces Educational Partnership with Vendavo -- "PPS Accepting Vendavo Pricing Knowledge Series Awards to Certified Pricing Professional Program"
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
Breaking Biology News(10 mins):